Department of Psychiatry, University Hospital 12 de Octubre, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
Eur Addict Res. 2011;17(5):262-70. doi: 10.1159/000324850. Epub 2011 Jun 23.
To evaluate the effectiveness of pregabalin as a tapering therapy on the subjective sleep quality of patients who underwent a benzodiazepine withdrawal program in routine medical practice.
Secondary analysis of a 12-week prospective, open noncontrolled study carried out in patients who met DSM-IV-TR criteria for benzodiazepine dependence. Sleep was evaluated with the Medical Outcomes Study Sleep Scale (MOS Sleep Scale).
282 patients were included in the analysis. Mean (±SD) pregabalin dose was 315 ± 166 mg/day at the end of the trial. We observed a significant and clinically relevant improvement in sleep outcomes at the endpoint, with a total score reduction from 55.8 ± 18.9 to 25.1 ± 18.0 at week 12 (i.e. a 55% reduction). Similar findings were apparent using the six dimensions of the MOS Sleep Scale. Moderate correlations were observed between the MOS Sleep summary index and sleep domains, and there were improvements in anxiety symptoms and disease severity.
These findings suggest that pregabalin may improve subjective sleep quality in patients who underwent a benzodiazepine withdrawal program. This effect appears to be partly independent of improvements in symptoms of anxiety or withdrawal. However, controlled studies are needed to establish the magnitude of the effect of pregabalin.
评估普瑞巴林作为常规医疗实践中苯二氮䓬类药物戒断计划患者的逐渐减量治疗对主观睡眠质量的有效性。
对符合 DSM-IV-TR 苯二氮䓬类药物依赖标准的患者进行为期 12 周的前瞻性、开放、非对照研究的二次分析。睡眠采用医疗结局研究睡眠量表（MOS 睡眠量表）进行评估。
282 例患者纳入分析。试验结束时，普瑞巴林的平均（±SD）剂量为 315±166mg/天。我们观察到终点时睡眠结果有显著且具有临床意义的改善，总评分从 55.8±18.9 降至 12 周时的 25.1±18.0（即降低 55%）。MOS 睡眠量表的六个维度也出现了类似的发现。MOS 睡眠综合指数与睡眠域之间存在中度相关性，焦虑症状和疾病严重程度也有所改善。
这些发现表明，普瑞巴林可能改善苯二氮䓬类药物戒断计划患者的主观睡眠质量。这种作用似乎部分独立于焦虑或戒断症状的改善。然而，需要进行对照研究来确定普瑞巴林的影响程度。
